Nucleic Acid News and Research

RSS

New method based on mass sequencing can detect hereditary breast and ovarian cancer syndrome

Researchers of the Catalan Institute of Oncology (ICO) at the Bellvitge Biomedical Research Institute (IDIBELL) have developed and validated a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The model is based on a genetic and bioinformatic analysis which has been proved very effective.

17 Jan 2013

FDA clears Hologic's APTIMA Trichomonas vaginalis Assay

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing its APTIMA Trichomonas vaginalis Assay on the Company's fully-automated PANTHER System.

From Hologic, Inc. 15 Jan 2013

Roche, PSS partner to develop fully automated emulsion PCR instrument for sequencing

Roche and Precision System Science, Co., Ltd (PSS) today announced the signing of an exclusive agreement to develop and manufacture a fully automated emulsion PCR instrument for Roche's portfolio of next-generation sequencing platforms. It is intended to support Roche's GS Junior and GS FLX+ systems as well as the sequencing platforms that Roche is currently developing.

From Roche Sequencing and Life Science 21 Dec 2012

CNIO creates 2 new databases to study the human genome

Scientists from the Structural Computational Biology Group at the Spanish National Cancer Research Centre (CNIO), led by Alfonso Valencia, together with French and American researchers, have published recently two articles in the journal Nucleic Acid Research (NAR) that introduce two new databases for studying the human genome.

18 Dec 2012

Meridian completes beta trials for two new illumigene molecular amplification tests

Meridian Bioscience, Inc. today announced that it has successfully completed beta trials for two new illumigene molecular amplification tests.

14 Dec 2012

3M Molecular detection assay Salmonella certified by AFNOR Certification

3M Food Safety today announced its 3M™ Molecular Detection Assay Salmonella received an NF VALIDATION mark from AFNOR Certification. The Salmonella assay was among three pathogen test kits the company introduced alongside its novel 3M™ Molecular Detection System less than a year ago. In April, AOAC Research Institute granted PTM SM certification of the Salmonella assay, another important confirmation of the technology's effectiveness in detecting the bacteria.

13 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.

26 Nov 2012

Scientists develop new prototype ultra sensitive disease sensor

Scientists have developed a prototype ultra-sensitive sensor that would enable doctors to detect the early stages of diseases and viruses with the naked eye, according to research published today in the journal Nature Nanotechnology.

29 Oct 2012

Global anti-tuberculosis campaign now ‘at a crossroads’

Tuberculosis care and control has improved dramatically over the last two decades, but numbers of cases and deaths are still high and multidrug resistant-TB is an under-reported and ever-increasing problem, suggest findings from the World Health Organization Global TB Report 2012.

18 Oct 2012

Thermo Fisher Scientific introduces MYECL Imager instrument

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific MYECL Imager, an easy-to-use imaging instrument that delivers one-touch image capture and analysis of protein and nucleic acid gels and Western blots.

From Thermo Fisher Scientific Inc. 17 Oct 2012

Roche announces availability of new HIV-1 viral load test in the U.S.

Roche announced today the U.S. availability of a new HIV-1 viral load test based on the company's proprietary dual-target approach. The COBAS TaqMan HIV-1 Test v2.0 for use with the High Pure System enables labs to combine an FDA-approved process for manual specimen preparation with an automated real-time PCR analyzer for amplification and detection.

From Roche Sequencing and Life Science 4 Oct 2012

Thermo Fisher Scientific announces opening of Molecular Biology Center of Excellence in Lithuania

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its Molecular Biology Center of Excellence in Vilnius, Lithuania.

From Thermo Fisher Scientific Inc. 20 Sep 2012

DNA synthesis methods: an interview with Clemens Richert

Automated DNA synthesis has been around for almost three decades. The key difference between the established methodology for making oligodeoxynucleotides (short stretches of single-stranded DNA) and our method is the template strand.

7 Sep 2012

Akonni receives NSF's Phase 2 SBIR Grant to develop Lab-on-a-Film microarray

Akonni Biosystems, a life science tools / molecular diagnostics company that develops, manufactures, and plans to market molecular testing devices for diagnosing infectious diseases and human genetic disorders, announced today the receipt of a $498,780 Phase 2 SBIR Grant from the National Science Foundation (NSF).

6 Sep 2012

People with guanine version of rs55705857 SNP more likely to develop gliomas

People who carry a "G" instead of an "A" at a specific spot in their genetic code have roughly a six-fold higher risk of developing certain types of brain tumors, a Mayo Clinic and University of California, San Francisco study has found. The

27 Aug 2012

ACS National Meeting & Exposition focuses on DNA wires and their potential use in identifying diseases

In a discovery that defies the popular meaning of the word "wire," scientists have found that Mother Nature uses DNA as a wire to detect the constantly occurring genetic damage and mistakes that ― if left unrepaired ― can result in diseases like cancer and underpin the physical and mental decline of aging.

20 Aug 2012

Antisense therapy shows promise in treating toxoplasmosis

A targeted approach to treating toxoplasmosis, a parasitic disease, shows early promise in test-tube and animal studies, where it prevented the parasites from making selected proteins. When tested in newly infected mice, it reduced the number of viable parasites by more than 90 percent, researchers from the University of Chicago Medicine report in the Proceedings of the National Academy of Sciences.

14 Aug 2012

Roche MagNA Pure 96 System's CE certified IVD version launched

Today, Roche announced the launch of its new CE certified IVD version of the MagNA Pure 96 System for automated sample preparation. By providing a maximum of lot-to-lot consistency and highest quality, the new MagNA Pure 96 System is designed to even better fulfill the needs of diagnostic customers. In 2011, the IVD version of MagNA Pure 96 was already introduced in the US.

From Roche Sequencing and Life Science 13 Aug 2012

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

26 Jul 2012